Caris Life Sciences (NasdaqGS:CAI) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsBobby Hill - CCOBrian Brille - Vice Chairman and EVPColleen Babington - Equity Research AssociateDavid Spetzler - PresidentLuke Power - CFOMichael Ryskin - Managing DirectorPatrick Donnelly - Managing Director, Equity ResearchRuss Denton - General CounselSubbu Nambi - Managing Director and Healthcare Equity ResearchVijay Kumar - Senior Managing DirectorConference Call ParticipantsDaniel Brennan - Senio ...

Caris Life Sciences (NasdaqGS:CAI) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsBobby Hill - CCOBrian Brille - Vice Chairman and EVPColleen Babington - Equity Research AssociateDavid Spetzler - PresidentLuke Power - CFOMichael Ryskin - Managing DirectorPatrick Donnelly - Managing Director, Equity ResearchRuss Denton - General CounselSubbu Nambi - Managing Director and Healthcare Equity ResearchVijay Kumar - Senior Managing DirectorConference Call ParticipantsDaniel Brennan - Senio ...

Caris Life Sciences (NasdaqGS:CAI) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker9Everyone, and welcome to the Caris Life Sciences Q4 2025 earnings call. My name is Dana, and I will be your coordinator today. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising that your han ...

Summary of Caris Life Sciences FY Conference Call Company Overview - **Company**: Caris Life Sciences (NasdaqGS:CAI) - **Date of Conference**: January 12, 2026 - **Key Speakers**: Brian Brille (Vice Chairman), David Spetzler (President), Luke Power (CFO) Key Points Financial Performance - Caris ended the year with over **$800 million** in cash, reflecting a **5% increase** through the quarter [2][3] - Revenue for Q4 was **$281 million**, representing a **116% year-over-year growth** [16][27] - The average selling price (ASP) for tissue tests increased to **$3,800** from **$3,500** in Q3, while blood tests rose to **$2,500** [34][60] Market Position and Growth Opportunities - The therapy selection business remains a core growth engine with consistent clinical case volumes and increasing pricing [4][15] - Caris completed nearly **200,000 genomic profiles** in the last year, achieving a **22% growth** in case volume [5][15] - The total addressable market (TAM) for therapy selection is large and underpenetrated, with only about **one-third** of patients receiving comprehensive genomic profiling [6][7] Product Development and Pipeline - Caris is focused on multi-cancer early detection (MCED) with promising initial results from the **AchieveOne** study, which is expected to read out by the end of the quarter [16][18] - The company is also launching **Caris ChromaSEQ**, a whole genome and whole transcriptome technology for hematological malignancies, currently under review by MolDX [19][20] - New product **MyClarity** aims to improve recurrence risk assessment for women post-surgery using AI and multimodal data [21][23] Strategic Partnerships - Caris announced a significant partnership with **Genentech**, involving a milestone payment of **$20 million** and a total contract value exceeding **$1 billion** [25] - The partnership aims to leverage Caris's data and technical capabilities to identify new drug targets [25] Commercial Strategy - The company plans to expand its commercial organization by **20%-25%** to enhance market reach and support growth [30][45] - Caris is committed to a patient-first philosophy, focusing on technology and service to cancer centers [10][11] Challenges and Future Outlook - The company acknowledges the need for insurance payers to update their medical policies regarding molecular profiling [29][30] - Caris is optimistic about the growth trajectory for 2026, driven by its technology leadership and product pipeline [15][32] Additional Insights - The market for comprehensive genomic profiling is recognized as the standard of care, with increasing demand for precision oncology programs [7][8] - Caris emphasizes the importance of maximizing biological information for patients, regardless of initial costs [17][19] - The company is focused on maintaining capital efficiency while investing in technology and commercial growth [30][45] This summary encapsulates the key insights and strategic directions discussed during the Caris Life Sciences FY Conference Call, highlighting the company's financial performance, market opportunities, product pipeline, and future outlook.